Journal of Bone and Mineral Metabolism

, Volume 26, Issue 1, pp 34–41

The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis

  • Hansheng Ding
  • Nobuo Koinuma
  • Matt Stevenson
  • Michiya Ito
  • Yasutake Monma


We constructed a mathematical model for assessing the cost-effectiveness of providing BMD (bone mineral density) scans to Japanese women aged 55 years and over and treating, with risedronate, those that are shown to be osteoporotic. Fracture rates, cost data, utility values, and the increased risks of fractures associated with T-score and vertebral fracture history were taken from published literature. We estimated the cost of fractures avoided due to risedronate treatment, allowing the net changes in cost, incorporating both intervention and fracture costs to be calculated. The QALYs (quality adjusted life years) gained through treatment were calculated enabling cost per QALY ratios to be presented. Further analyses were undertaken assuming treatment was reserved for older women and/or those who had sustained a vertebral fracture in the previous 2 years. Cost per QALY values were inversely related to absolute risk of fracture. Assuming a cost per QALY value threshold of US$100,000, we concluded that providing BMD scans to women aged 70 years and over who had sustained a vertebral fracture in the previous 2 years and treating those that were osteoporotic was cost-effective. However, providing BMD scans for women without a vertebral fracture in the previous 2 years was not cost-effective, even in women aged 85 years and older.

Key words

cost-effectiveness analysis osteoporosis fracture risedronate Japan 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kishimoto, H 2005Change in the definition of osteoporosis especially on bone qualityClin Calcium15736740PubMedGoogle Scholar
  2. 2.
    Anonymous1997Who are candidates for prevention and treatment for osteoporosis?Osteoporos Int716Google Scholar
  3. 3.
    Anonymous1993Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosisAm J Med94646650CrossRefGoogle Scholar
  4. 4.
    Kanis, JA 1994Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study GroupOsteoporos Int4368381PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis, JA, Gluer, CC 2000An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis FoundationOsteoporos Int11192202PubMedCrossRefGoogle Scholar
  6. 6.
    Schuit, SC, van der Klift, M, Weel, AE, de Laet, CE, Burger, H, Seeman, E, Hofman, A, Uitterlinden, AG, van Leeuwen, JP, Pols, HA 2004Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam StudyBone (NY)34195202Google Scholar
  7. 7.
    Orimo, H, Hayashi, Y, Fukunaga, M, Sone, T, Fujiwara, S, Shiraki, M, Kushida, K, Miyamoto, S, Soen, S, Nishimura, J, Oh-Hashi, Y, Hosoi, T, Gorai, I, Tanaka, H, Igai, T, Kishimoto, H 2001Diagnostic criteria for primary osteoporosis: year 2000 revisionJ Bone Miner Metab19331337PubMedCrossRefGoogle Scholar
  8. 8.
    Ray, NF, Chan, JK, Thamer, M, Melton, LJ,III 1997Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis FoundationJ Bone Miner Res122435PubMedCrossRefGoogle Scholar
  9. 9.
    Melton, LJ,III 1993Hip fractures: a worldwide problem today and tomorrowBone (NY)14S1S8Google Scholar
  10. 10.
    Hayashi, Y 2004Health economics of treatment of osteoporosis (in Japanese)Geriatr Med42613618Google Scholar
  11. 11.
    Lindsay, R 1995The burden of osteoporosis: costAm J Med989S11SPubMedCrossRefGoogle Scholar
  12. 12.
    Eastell, R, Boyle, IT, Compston, J, Cooper, C, Fogelman, I, Francis, RM, Hosking, DJ, Purdie, DW, Ralston, S, Reeve, J, Reid, DM, Russell, RG, Stevenson, JC 1998Management of male osteoporosis: report of the UK Consensus GroupQ J Med917192Google Scholar
  13. 13.
    Cummings, SR, Rubin, SM, Black, D 1990The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogenClin Orthop Relat Res252163166PubMedGoogle Scholar
  14. 14. Scholar
  15. 15.
    Whang, W, Sisk, JE, Heitjan, DF, Moskowitz, AJ 1999Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderlyInt J Technol Assess Health Care15563572PubMedGoogle Scholar
  16. 16.
    Marcus, R, Wong, M, Heath, H,III, Stock, JL 2002Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpointEndocr Rev231637PubMedCrossRefGoogle Scholar
  17. 17.
    Harris, ST, Watts, NB, Genant, HK, McKeever, CD, Hangartner, T, Keller, M, Chesnut, CH,III, Brown, J, Eriksen, EF, Hoseyni, MS, Axelrod, DW, Miller, PD 1999Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA28213441352PubMedCrossRefGoogle Scholar
  18. 18.
    Levy, P, Levy, E, Audran, M, Cohen-Solal, M, Fardellone, P, Le Parc, JM 2002The cost of osteoporosis in men: the French situationBone (NY)30631636Google Scholar
  19. 19.
    Krappweis, J, Rentsch, A, Schwarz, UI, Krobot, KJ, Kirch, W 1999Outpatient costs of osteoporosis in a national health insurance populationClin Ther2120012014PubMedCrossRefGoogle Scholar
  20. 20.
    Martin, BC, Chisholm, MA, Kotzan, JA 2001Isolating the cost of osteoporosis-related fracture for postmenopausal women. A population-based studyGerontology472129PubMedCrossRefGoogle Scholar
  21. 21.
    MHLW2004Patient Survey 2002 (in Japanese)Health and Welfare Statistics AssociationTokyo684Google Scholar
  22. 22. Scholar
  23. 23.
    MHLW2004Patient Survey 2002 (in Japanese)Health and Welfare Statistics AssociationTokyo49Google Scholar
  24. 24.
    Fujiwara, S, Kasagi, F, Masunari, N, Naito, K, Suzuki, G, Fukunaga, M 2003Fracture prediction from bone mineral density in Japanese men and womenJ Bone Miner Res1815471553PubMedCrossRefGoogle Scholar
  25. 25.
    Kushida, K, Fukunaga, M, Kishimoto, H, Shiraki, M, Itabashi, A, Inoue, T, Kaneda, K, Morii, H, Nawata, H, Yamamoto, K, Ohashi, Y, Orimo, H 2004A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trialJ Bone Miner Metab22469478PubMedGoogle Scholar
  26. 26.
    Shiraki, M, Fukunaga, M, Kushida, K, Kishimoto, H, Taketani, Y, Minaguchi, H, Inoue, T, Morita, R, Morii, H, Yamamoto, K, Ohashi, Y, Orimo, H 2003A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)Osteoporos Int14225234PubMedGoogle Scholar
  27. 27.
    Majima, T, Komatsu, Y, Doi, K, Takagi, C, Shigemoto, M, Fukao, A, Morimoto, T, Corners, J, Nakao, K 2006Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' diseaseJ Bone Miner Metab24105113PubMedCrossRefGoogle Scholar
  28. 28.
    Sato, Y, Iwamoto, J, Kanoko, T, Satoh, K 2005Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after strokeArch Intern Med16517431748PubMedCrossRefGoogle Scholar
  29. 29.
    Reginster, J, Minne, HW, Sorensen, OH, Hooper, M, Roux, C, Brandi, ML, Lund, B, Ethgen, D, Pack, S, Roumagnac, I, Eastell, R 2000Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int118391PubMedCrossRefGoogle Scholar
  30. 30.
    McClung, MR, Geusens, P, Miller, PD, Zippel, H, Bensen, WG, Roux, C, Adami, S, Fogelman, I, Diamond, T, Eastell, R, Meunier, PJ, Reginster, JY 2001Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med344333340PubMedCrossRefGoogle Scholar
  31. 31.
    Institute SIR2006Remuneration Standard for Medical Services, version 4Japan Social Insurance Research InstituteTokyo162Google Scholar
  32. 32.
    Jibou2004National Health Insurance Price List (in Japanese)Jibou PressTokyoGoogle Scholar
  33. 33.
    Stevenson MD, Davis S (2005) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. http://wwwniceorguk/pageaspx?o=370643. Accessed 2006/12/12Google Scholar
  34. 34.
    Fukunaga, M, Kushida, K, Kishimoto, H, Shiraki, M, Taketani, Y, Minaguchi, H, Inoue, T, Morita, R, Morii, H, Yamamoto, K, Ohashi, Y, Orimo, H 2002A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trialOsteoporos Int13971979PubMedCrossRefGoogle Scholar
  35. 35.
    Clemmesen, B, Ravn, P, Zegels, B, Taquet, AN, Christiansen, C, Reginster, JY 1997A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosisOsteoporos Int7488495PubMedCrossRefGoogle Scholar
  36. 36.
    MHLW2004Social medical insurance reimbursement survey 2002 (in Japanese)Health and Welfare Statistics AssociationTokyoGoogle Scholar
  37. 37.
    MHLW2004Report of long-term care insurance payment 2002 (in Japanese)Health and Welfare Statistics AssociationTokyoGoogle Scholar
  38. 38.
    Rahman, M, Sekimoto, M, Takamatsu, I, Hira, K, Shimbo, T, Toyoshima, K, Fukui, T 2001Economic evaluation of universal BCG vaccination of Japanese infantsInt J Epidemiol30380385PubMedCrossRefGoogle Scholar
  39. 39.
    Weinstein, MC, Stason, WB 1977Foundations of cost-effectiveness analysis for health and medical practicesN Engl J Med296716721PubMedCrossRefGoogle Scholar
  40. 40.
    Kurimori, S, Fukuda, Y, Nakamura, K, Watanabe, M, Takano, T 2006Calculation of prefectural disability-adjusted life expectancy (DALE) using long-term care prevalence and its socioeconomic correlates in JapanHealth Policy76346358PubMedCrossRefGoogle Scholar
  41. 41.
    Yoh, K, Tanaka, K, Ishikawa, A, Ishibashi, T, Uchino, Y, Sato, Y, Tobinaga, M, Hasegawa, N, Kamae, S, Yoshizawa, M 2005Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatmentJ Bone Miner Metab23167173PubMedCrossRefGoogle Scholar
  42. 42.
    MHLW2004Patient survey 2002 (in Japanese)Health and Welfare Statistics AssociationTokyo430431472–473Google Scholar
  43. 43.
    MHLW2004Patient survey 2002 (in Japanese)Health and Welfare Statistics AssociationTokyo434435476–477Google Scholar
  44. 44.
    Klotzbuecher, CM, Ross, PD, Landsman, PB, Abbott, TA,III, Berger, M 2000Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res15721739PubMedCrossRefGoogle Scholar
  45. 45.
    Kanis, JA, Johnell, O, Oden, A, Borgstrom, F, Zethraeus, N, De Laet, C, Jonsson, B 2004The risk and burden of vertebral fractures in SwedenOsteoporos Int152026PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2008

Authors and Affiliations

  • Hansheng Ding
    • 1
    • 2
  • Nobuo Koinuma
    • 1
  • Matt Stevenson
    • 3
  • Michiya Ito
    • 1
  • Yasutake Monma
    • 1
  1. 1.Department of Health Administration and Policy, Graduate School of MedicineTohoku UniversitySendaiJapan
  2. 2.Aetna School of ManagementShanghai Jiao Tong UniversityChina
  3. 3.School of Health and Related ResearchUniversity of SheffieldSheffieldUK

Personalised recommendations